Zevra Therapeutics Inc (NASDAQ: ZVRA) kicked off on Friday, down -6.92% from the previous trading day, before settling in for the closing price of $8.96. Over the past 52 weeks, ZVRA has traded in a range of $6.19-$13.16.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 29.64%. While this was happening, its average annual earnings per share was recorded 154.82%. With a float of $55.84 million, this company’s outstanding shares have now reached $56.22 million.
Zevra Therapeutics Inc (ZVRA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Zevra Therapeutics Inc is 0.81%, while institutional ownership is 71.23%. The most recent insider transaction that took place on Oct 10 ’25, was worth 210,908. In this transaction President and CEO of this company sold 19,500 shares at a rate of $10.82, taking the stock ownership to the 222,016 shares. Before that another transaction happened on Oct 10 ’25, when Company’s Director proposed sale 19,500 for $10.82, making the entire transaction worth $210,990.
Zevra Therapeutics Inc (ZVRA) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.69 earnings per share (EPS), lower than consensus estimate (set at -0.4) by -0.29. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 154.82% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
Take a look at Zevra Therapeutics Inc’s (ZVRA) current performance indicators. Last quarter, stock had a quick ratio of 8.57. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.63, a number that is poised to hit 0.05 in the next quarter and is forecasted to reach 0.56 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
As of the previous 9 days, the stock’s Stochastic %D was 73.91%.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 24.23%, which indicates a significant decrease from 32.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.36 in the past 14 days, which was lower than the 0.51 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.09, while its 200-day Moving Average is $9.15. Nevertheless, the first resistance level for the watch stands at $8.81 in the near term. At $9.28, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.53. If the price goes on to break the first support level at $8.08, it is likely to go to the next support level at $7.83. Should the price break the second support level, the third support level stands at $7.36.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
The company with the Market Capitalisation of 469.52 million has total of 56,298K Shares Outstanding. Its annual sales at the moment are 23,610 K in contrast with the sum of -105,510 K annual income. Company’s last quarter sales were recorded 26,060 K and last quarter income was -540 K.
